Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Meredith Lightfoot

Urology Plano, TX Medical Doctor

NPI 1083661052 CMS profile 140192

6124 W Parker Rd, Ste 434, Plano, TX 75093

Open in the dashboard

General payments

$9,097

458 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Meredith Lightfoot of Plano, TX is reported in the CMS Open Payments database as having received $9,097 across 458 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,530 124
2024 General $1,936 83
2023 General $1,405 73
2022 General $1,226 63
2021 General $816 39
2020 General $348 23
2019 General $835 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meredith Lightfoot
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Meredith Lightfoot were reported at $2,530. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Meredith Lightfoot Urology median Middle half National median
2019 $835 $480 $147–$1,201 $163
2020 $348 $246 $87–$645 $114
2021 $816 $358 $111–$1,000 $132
2022 $1,226 $476 $143–$1,263 $149
2023 $1,405 $560 $168–$1,461 $160
2024 $1,936 $563 $170–$1,464 $164
2025 $2,530 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $1,259 87 payments
  2. Sumitomo Pharma America, Inc. $1,222 65 payments
  3. Janssen Biotech, Inc. $891 30 payments
  4. AbbVie, Inc. $825 54 payments
  5. Dendreon Pharmaceuticals LLC $620 26 payments
  6. Ferring Pharmaceuticals Inc. $401 16 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $394 21 payments
  8. Urovant Sciences Inc $335 16 payments
  9. Pfizer Inc. $323 17 payments
  10. Axonics Modulation Technologies, Inc. $233 9 payments
  11. Other $2,594 117 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,781 451 payments
  2. Education $317 7 payments
Products named General payments · program years 2019–2025
  1. MYRBETRIQ $1,072 74 payments
  2. GEMTESA $1,061 62 payments
  3. ERLEADA $710 26 payments
  4. XTANDI $654 38 payments
  5. PROVENGE $620 26 payments
  6. BOTOX $539 44 payments
  7. ORGOVYX Hormone Therapy $455 19 payments
  8. Nubeqa $394 21 payments
  9. ADSTILADRIN $360 14 payments
  10. ORGOVYX Oncology $230 11 payments
  11. Other $3,645 163 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

3,413

Median for Urology: 1,053

Drug cost

$882,974

Median for Urology: $101,464

Branded share of claims

49.7%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 487 $439,035
Xtandi Enzalutamide Brand 11 $153,844
Gemtesa Vibegron Brand 128 $131,957
Orgovyx Relugolix Brand 14 $34,023
Estradiol Generic 550 $33,556
Mirabegron Er Mirabegron Brand 51 $32,635
Solifenacin Succinate Generic 506 $27,972
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 360 $9,525
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 313 $4,403
Oxybutynin Chloride Er Oxybutynin Chloride Brand 185 $3,801

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 88 billing codes

Paid by Medicare

$362,552

Of which drugs: $69,015

Medicare patients

1,124

Average age 76

Services billed

21,015

938 women, 186 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Depression 27%
Diabetes 26%
Ischemic heart disease 26%
Chronic kidney disease 26%
Osteoporosis 23%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 52 11,900 $58,966
Injection, garamycin, gentamicin, up to 80 mg J1580 Office 18 58 $98
Injection, ceftriaxone sodium, per 250 mg J0696 Office 14 97 $33

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $336
$336 — 11,900
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $228
$228 — —
PROVENGE
  • Dendreon Pharmaceuticals LLC $187
$187 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $151
  • PFIZER INC. $28
$179 14 —
GEMTESA
  • Sumitomo Pharma America, Inc. $79
$79 128 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

458 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record